Welcome To The Mannkind HUB On AGORACOM
Edit this title from the Fast Facts Section
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM Best Of The Best Small Cap TV – August 29, 2014

Summer end selling season is now upon us and small cap investors have an opportunity to buy oversold companies at a bargain.

In this special episode of AGORACOM Best Of The Best Small Cap TV, George (Founder) and Allan (Chief Market Commentator) give their Top 5 Summer End Selling Candidates (+ 1 Bonus Pick) that are most likely to provide a pop to their portfolios by October 31, 2014.  There is a lot on the line in the wager between the two, with each providing completely different picks from the other and some great potential trades for viewers.

Watch It Now!

Message: Afrezza sales could be higher than Exubera, says Summer Street

Barney-fife-crop-fix
Rank: [?]
President
Points: [?]
5492
Rating: [?]
Votes: 21 Score: 4.5
  • Currently 4.5/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Afrezza sales could be higher than Exubera, says Summer Street

posted on Jul 16, 13 09:52AM

"Summer Street believes that if approved, sales of MannKind's (MNKD) inhalable insulin Afrezza could be "substantially higher" than Pfizer’s (PFE) Exubera given Afrezza’s ease of use. However, the firm adds that it cannot accurately predict future sales of Afrezza at this time."

http://www.theflyonthewall.com/permalinks/entry.php/MNKD;PFEid1858409/MNKD;PFE-Afrezza-sales-could-be-higher-than-Exubera-says-Summer-Street

New Message

Please login to post a reply

AGORACOM Quick Tips

Start A New HUB. Control. Quality. Refreshing. ... Start One Now

President's D.D.

Here's the latest Griffin report read more

Stock Quote

Hub Leaders